Retraction of scientific publictions (February 2010)

Retraction: Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children.

The paper cited above was retracted by the publisher based on the conclusion from the UK general medical council. Some data in the original paper were not correct and moreover, the study was not approved by local ethics committee. The paper was published in 1998 by Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, Berelowitz M, Dhillon AP, Thomson MA, Harvey P, Valentine A, Davies SE, Walker-Smith JA.

Journal: Lancet , February 2010.

Retraction: Triplex-forming oligonucleotide-orthophenanthroline conjugates for efficient targeted genome modification.

The above paper was retracted by the authors. The first author admitted falsification of data showing in the study. The original paper was published in 2008 by Cannata F, Brunet E, Perrouault L, Roig V, Ait-Si-Ali S, Asseline U, Concordet J-P, and Giovannangeli C.

Journal: Proc Natl Acad Sci U S A. , February 2010.

Retraction: Identification of calcium-modulating cyclophilin ligand as a human host restriction to HIV-1 release overcome by Vpu.

The paper was retracted by the corresponding author due to inability to reproduce the data and contradictory findings to other labs. The first two authors, however, declined to sign the retraction.The paper was published in 2008 by Varthakavi V, Heimann-Nichols E, Smith RM, Sun Y, Bram RJ, Ali S, Rose J, Ding L and Spearman P.

Journal: Nat Med , February 2010.

January 2009    February 2009    March 2009    April 2009    May 2009    June 2009    July 2009    August 2009    September 2009    October 2009    November 2009    December 2009    January 2010    February 2010    March 2010    April 2010    May 2010    June 2010    July 2010   
Site News
New feature:
You can add comments on protocols now. Just go to any individual method page and click on the "Add a comment" link.

Highlight of the month
Metformin: New mechanism of old drug

Metformin, one of the most effective antidiabetic drugs, remains on market for a long time. Yet, the mechanisms of action are still elusive. Past studies point to LKB1/AMPK axis as the mediator of gluoneogenesis regulation. A recent report challenges this notion and provides evidence suggesting metformin can function in the absence of LKB1/AMPK.

Foretz and colleagues found metformin suppresses glucose production in wildtype primary hepatocytes dose-dependently. To their surprise, this suppression remains effective in AMPK deficient hepatocytes. They went further to show there is no difference between wildtype and AMPK liver specific knockout mice for glucose regulation by metformin. Similarly, LKB1, the upstream kinase of AMPK, is not required for glucose lowering effects of metformin in hepatocytes and in animals. More importantly, Foretz et al found metformin treatment reduces energy state of primary hepatocytes and in livers of mice, which is probably the primary reason of decreased glucose production.

The new mechanism proposed by Foretz et al raises number of interesting questions, such as the target of metformin, the mitochondria changes after treatment, beta oxidation, glycolysis. Answers for them will provide more insights about the action of metformin and clear understanding of type II diabetes. ... Read more highlights.